Long-term safety and efficacy of certolizumab pegol in combination with methotrexate in the treatment of rheumatoid arthritis: 5-year results from the RAPID 1 trial and open-label...

por Keystone, Edward, Landewé, Robert, van Vollenhoven, Ronald, Combe, Bernard, Strand, Vibeke, Mease, Philip, Shaughnessy, Laura, VanLunen, Brenda, van der Heijde, Désirée
Publicado 2014

Effectiveness and safety of 12-month certolizumab pegol treatment for axial spondyloarthritis in real-world clinical practice in Europe

por Baraliakos, Xenofon, Witte, Torsten, De Clerck, Luc, Frediani, Bruno, Collantes-Estévez, Eduardo, Katsifis, Gkikas, VanLunen, Brenda, Kleine, Elisabeth, Hoepken, Bengt, Bauer, Lars, Goodson, Nicola
Publicado 2020

The impact of certolizumab pegol treatment on the incidence of anterior uveitis flares in patients with axial spondyloarthritis: 48-week interim results from C-VIEW

por van der Horst-Bruinsma, Irene, van Bentum, Rianne, Verbraak, Frank D, Rath, Thomas, Rosenbaum, James T, Misterska-Skora, Maria, Hoepken, Bengt, Irvin-Sellers, Oscar, VanLunen, Brenda, Bauer, Lars, Rudwaleit, Martin
Publicado 2020

A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis

por Weinblatt, Michael E., Bingham, Clifton O., Burmester, Gerd‐Rüdiger, Bykerk, Vivian P., Furst, Daniel E., Mariette, Xavier, van der Heijde, Désirée, van Vollenhoven, Ronald, VanLunen, Brenda, Ecoffet, Cécile, Cioffi, Christopher, Emery, Paul
Publicado 2017